Qualigen Therapeutics Inc
NASDAQ:QLGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Qualigen Therapeutics Inc
Additional Paid In Capital
Qualigen Therapeutics Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
Additional Paid In Capital
$122.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$22.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$8.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
35%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$14B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
Qualigen Therapeutics Inc
Glance View
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
See Also
What is Qualigen Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
122.9m
USD
Based on the financial report for Jun 30, 2025, Qualigen Therapeutics Inc's Additional Paid In Capital amounts to 122.9m USD.
What is Qualigen Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
12%
Over the last year, the Additional Paid In Capital growth was 6%. The average annual Additional Paid In Capital growth rates for Qualigen Therapeutics Inc have been 5% over the past three years , 18% over the past five years , and 12% over the past ten years .
